Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study of PGN EDODM1 for myotonic dystrophy type 1

Next Previous
Trial Profile

A Clinical Study of PGN EDODM1 for myotonic dystrophy type 1

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PGN-EDODM1 (Primary)
  • Indications Myotonic dystrophy
  • Focus Adverse reactions; First in man
  • Acronyms FREEDOM-EDODM1
  • Sponsors Pepgen Corporation

Most Recent Events

  • 08 Aug 2023 According to a Pepgen Corporation media release, the company continue to pursue global strategy of initiating FREEDOM-EDODM1 clinical study in geographies outside the U.S
  • 13 Jun 2023 According to a Pepgen Corporation media release, the company awaits receipt of an official clinical hold letter from US FDA and withdraw its prior guidance with respect to the timeline for initiating trial in first half of 2023.
  • 30 May 2023 Status changed from planning to suspended, according to a Pepgen Corporation media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top